Overview

Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib

Status:
Completed
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
This study will observe the degree of the quality of life in non-transplant candidate patients with multiple myeloma before and after bortezomib administration by using EORTC-QLQ C30 (European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Core30) and EQ-5D (EuroQol-5 Dimensions). Both tools are validated research instruments used to measure the quality of life in cancer patients and consequently will provide fundamental data regarding the quality of life in patients with multiple myeloma by analyzing factors that affect the quality of life.
Details
Lead Sponsor:
Janssen Korea, Ltd., Korea
Treatments:
Bortezomib